The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Triple-Negative Breast Cancer: An Unmet Medical Need
Abstract
Triple-negative breast cancer, characterized by tumors that do not express estrogen receptor (ER), progesterone receptor (PR), or HER-2 genes, represents an important clinical challenge because these cancers do not respond to endocrine therapy or other available targeted agents. The metastatic potential in triple-negative breast cancer is similar to that of other breast cancer subtypes, but these tumors are associated with a shorter median time to relapse and death. One important goal is therefore the identification of prognostic factors and markers to reliably select high and low risk subsets of patients with triple-negative disease for different treatment approaches of subtypes with differential responsiveness to specific agents. However, a reliable prognostic marker has been elusive, and markers have been inconsistently useful. For example, epidermal growth factor receptor (EGFR) has been studied, but there is still a lack of agreement on a standard assay or cutoff for EGFR expression levels with respect to prognosis. Similarly, because triple-negative status is sometimes used as a surrogate for basal-like breast cancer, specific basal markers have been explored. Indeed, trials designed to accrue patients with basal-like breast cancer using ER/PR and HER-2 negativity may provide only an approximation of the triple-negative population and are sometimes reanalyzed using more specific indicators like CK 5/6, EGFR status, and others, again marred by discordances. Chemotherapy remains the mainstay of treatment of triple-negative breast cancer, but important limitations still need to be overcome in the next few years if any significant clinical strides are to be made. Current treatment strategies for triple-negative disease include anthracyclines, taxanes, ixabepilone, platinum agents, and biologic agents. More recently, EGFR inhibition has been proposed as a therapeutic mechanism in triple-negative breast cancer, again with mixed results. Agents that target poly(ADP-ribose) polymerase and androgen receptors have also been proposed in these patients or subsets of them, and ongoing trials should result in definitive guidance with respect to the value of these agents in triple-negative disease. Triple-negative breast cancer is clearly a distinct clinical subtype, from the perspective of both ER and HER-2 expression, but further subclassification is needed. At present, there is not a clear, proven effective single agent that targets a defining vulnerability in triple-negative breast cancer. This article will review the clinical problem of triple-negative disease, potential prognostic factors, demonstrated efficacy of currently available therapeutic options, and new potential therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Triple-negative breast cancer: clinical features and patterns of recurrence
Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P., & Narod, S. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3045 · Cited by 5,091
Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
Carey, L. A., Perou, C. M., Livasy, C. A., Dressler, L. G., Cowan, D., Conway, K., Karaca, G., Troester, M. A., Tse, C. K., Edmiston, S., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2492 · Cited by 3,819
Liedtke, C., Mazouni, C., Hess, K. R., André, F., Tordai, A., Mejia, J. A., Symmans, W. F., Gonzalez-Angulo, A. M., Hennessy, B., Green, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4147 · Cited by 2,892
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
Carey, L. A., Dees, E. C., Sawyer, L., Gatti, L., Moore, D. T., Collichio, F., Ollila, D. W., Sartor, C. I., Graham, M. L., & Perou, C. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1109 · Cited by 2,087
Bauer, K. R., Brown, M., Cress, R. D., Parise, C. A., & Caggiano, V. (2007) · Cancer · doi:10.1002/cncr.22618 · Cited by 2,067
Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
Rouzier, R., Perou, C. M., Symmans, W. F., Ibrahim, N., Cristofanilli, M., Anderson, K., Hess, K. R., Stec, J., Ayers, M., Wagner, P., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2421 · Cited by 1,891
Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R. K., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60892-6 · Cited by 1,655
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma
Livasy, C. A., Karaca, G., Nanda, R., Tretiakova, M. S., Olopade, O. I., Moore, D. T., & Perou, C. M. (2006) · Modern Pathology · doi:10.1038/modpathol.3800528 · Cited by 1,063
Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
Silver, D. P., Richardson, A. L., Eklund, A. C., Wang, Z. C., Szallasi, Z., Li, Q., Juul, N., Leong, C.-O., Calogrias, D., Buraimoh, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.4725 · Cited by 981
Neoadjuvant Chemotherapy in Breast Cancer: Significantly Enhanced Response With Docetaxel
Smith, I. C., Heys, S. D., Hutcheon, A. W., Miller, I. D., Payne, S., Gilbert, F. J., Ah-See, A. K., Eremin, O., Walker, L. G., Sarkar, T. K., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1456 · Cited by 782
HER2 and Response to Paclitaxel in Node-Positive Breast Cancer
Hayes, D. F., Thor, A. D., Dressler, L. G., Weaver, D., Edgerton, S., Cowan, D., Broadwater, G., Goldstein, L. J., Martino, S., Ingle, J. N., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071167 · Cited by 608
Self-citationDoane, A. S., Danso, M., Lal, P., Donaton, M., Zhang, L., Hudis, C., & Gerald, W. L. (2006) · Oncogene · doi:10.1038/sj.onc.1209415 · Cited by 603
Self-citationFossati, R., Confalonieri, C., Torri, V, Ghislandi, E., Penna, A., Pistotti, V, Tinazzi, A., & Liberati, A. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.10.3439 · Cited by 546
Hugh, J., Hanson, J., Cheang, M. C. U., Nielsen, T. O., Perou, C. M., Dumontet, C., Reed, J., Krajewska, M., Treilleux, I., Rupin, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1024 · Cited by 526
Burstein, H. J., Elias, A. D., Rugo, H. S., Cobleigh, M. A., Wolff, A. C., Eisenberg, P. D., Lehman, M., Adams, B. J., Bello, C. L., DePrimo, S. E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5375 · Cited by 489
Finn, R. S., Dering, J., Ginther, C., Wilson, C. A., Glaspy, P., Tchekmedyian, N., & Slamon, D. J. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9463-x · Cited by 409
Fulford, L. G., Easton, D. F., Reis‐Filho, J. S., Sofronis, A., Gillett, C. E., Lakhani, S. R., & Hanby, A. (2006) · Histopathology · doi:10.1111/j.1365-2559.2006.02453.x · Cited by 352
Buzdar, A. U., Singletary, S. E., Theriault, R. L., Booser, D. J., Valero, V., Ibrahim, N., Smith, T. L., Asmar, L., Frye, D., Manuel, N., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3412 · Cited by 242
Carey, L. A., Rugo, H. S., Marcom, P. K., Irvin, W., Ferraro, M., Burrows, E., He, X., Perou, C. M., & Winer, E. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.1009 · Cited by 163
Phase II Genomics Study of Ixabepilone as Neoadjuvant Treatment for Breast Cancer
Baselga, J. M., Zambetti, M., Llombart‐Cussac, A., Manikhas, G., Kubista, E., Steger, G. G., Makhson, A. N., Tjulandin, S., Ludwig, H., Verrill, M. W., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.2646 · Cited by 113
Sikov, W. M., Dizon, D. S., Strenger, R., Legare, R. D., Theall, K. P., Graves, T. A., Gass, J. S., Kennedy, T. A., & Fenton, M. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4163 · Cited by 108
A Phase I Study of Cetuximab/Paclitaxel in Patients with Advanced-Stage Breast Cancer
Modi, S., D’Andrea, G. M., Norton, L., Yao, T. J., Caravelli, J. F., Rosen, P., Hudis, C. A., & Seidman, A. D. (2006) · Clinical Breast Cancer · doi:10.3816/cbc.2006.n.040 · Cited by 104
Self-citationGluz, O., Nitz, U. A., Harbeck, N., Ting, E., Kates, R. E., Herr, A., Lindemann, W., Jackisch, C., Berdel, W. E., Kirchner, H. H., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm551 · Cited by 103
Torrisi, R., Balduzzi, A., Ghisini, R., Rocca, A., Bottiglieri, L., Giovanardi, F., Veronesi, P., Luini, A., Orlando, L., Viale, G., et al. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0652-z · Cited by 89
Therapeutic Strategies for Triple-Negative Breast Cancer
Tan, A. R., & Swain, S. M. (2008) · The Cancer Journal · doi:10.1097/ppo.0b013e31818d839b · Cited by 76
Bidard, F., Matthieu, M.-C., Chollet, P. J. M., Raoefils, I., Abrial, C., Dômont, J., Spielmann, M., Delaloge, S., André, F., & Penault-Llorca, F. M. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn039 · Cited by 63
Pivot, X. B., Li, R. K., Thomas, E. S., Chung, H. C., Fein, L. E., Chan, V. F., Jassem, J., de Mendoza, F. H., Mukhopadyay, P., & Roche, H. H. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.07.015 · Cited by 27
Loesch, D. M., Greco, F. A., Senzer, N. N., Burris, H. A., Hainsworth, J. D., Jones, S. E., Vukelja, S. J., Sandbach, J. F., Holmes, F. A., SEDLACEK, S. M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.1000 · Cited by 24
Leone, J. P., Guardiola, V., Venkatraman, A., Pegram, M. D., Welsh, C. F., Silva, O., Larrieux, R., Franchesci, D., Gómez, C., & Hurley, J. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.625 · Cited by 22
Cited by
ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition
Doll, S., Proneth, B., Tyurina, Y. Y., Panzilius, E., Kobayashi, S., Ingold, I., Irmler, M., Beckers, J., Aichler, M., Walch, A., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2239 · Cited by 4,293
Pembrolizumab for Early Triple-Negative Breast Cancer
Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910549 · Cited by 3,270
Greaves, M., & Maley, C. C. (2012) · Nature · doi:10.1038/nature10762 · Cited by 3,162
Emens, L. A., Cruz, C., Eder, J. P., Braiteh, F., Chung, C., Tolaney, S. M., Kuter, I., Nanda, R., Cassier, P. A., Delord, J.-P., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4224 · Cited by 766
Breast Cancer: Current Perspectives on the Disease Status
Fahad Ullah, M. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-20301-6_4 · Cited by 598
Metadata
- Authors
- Hudis, C. A., & Gianni, L.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-01-01
- Volume
- 16
- Issue
- S1
- Pages
- 1-11
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2125094267
- Cited by
- 780
- References
- 32
- FWCI
- 13.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.